首页 > 最新文献

Coronavirus Disease 2019 (COVID-19)最新文献

英文 中文
Biology of Coronaviruses and Predicted Origin of SARS-CoV-2 冠状病毒生物学与SARS-CoV-2的预测起源
Coronavirus Disease 2019 (COVID-19)
Pub Date : 2022-02-07 DOI: 10.1201/9781003190394-2
G. Palù, A. Reale, N. Bazan, P. Panda, V. Uversky, M. Seyran, A. Aljabali, S. Sherchan, G. Azad, W. Baetas-da-Cruz, P. Adadi, M. Tambuwala, B. Uhal, Kazuo Takayama, Ã. Serrano-Aroca, T. El-Aziz, A. Brufsky, K. Lundstrom
{"title":"Biology of Coronaviruses and Predicted Origin of SARS-CoV-2","authors":"G. Palù, A. Reale, N. Bazan, P. Panda, V. Uversky, M. Seyran, A. Aljabali, S. Sherchan, G. Azad, W. Baetas-da-Cruz, P. Adadi, M. Tambuwala, B. Uhal, Kazuo Takayama, Ã. Serrano-Aroca, T. El-Aziz, A. Brufsky, K. Lundstrom","doi":"10.1201/9781003190394-2","DOIUrl":"https://doi.org/10.1201/9781003190394-2","url":null,"abstract":"","PeriodicalId":10691,"journal":{"name":"Coronavirus Disease 2019 (COVID-19)","volume":"120 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75322530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Vaccine Development Strategies and the Current Status of COVID-19 Vaccines 疫苗开发策略及COVID-19疫苗现状
Coronavirus Disease 2019 (COVID-19)
Pub Date : 2022-02-07 DOI: 10.1201/9781003190394-13
Mohsen Akbarian, K. Lundstrom, E. Redwan, V. Uversky
{"title":"Vaccine Development Strategies and the Current Status of COVID-19 Vaccines","authors":"Mohsen Akbarian, K. Lundstrom, E. Redwan, V. Uversky","doi":"10.1201/9781003190394-13","DOIUrl":"https://doi.org/10.1201/9781003190394-13","url":null,"abstract":"","PeriodicalId":10691,"journal":{"name":"Coronavirus Disease 2019 (COVID-19)","volume":"59 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75378928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Computational Biology and Bioinformatics in Anti-SARS-CoV-2 Drug Development 抗sars - cov -2药物开发中的计算生物学和生物信息学
Coronavirus Disease 2019 (COVID-19)
Pub Date : 2022-02-07 DOI: 10.1201/9781003190394-11
V. Uversky
{"title":"Computational Biology and Bioinformatics in Anti-SARS-CoV-2 Drug Development","authors":"V. Uversky","doi":"10.1201/9781003190394-11","DOIUrl":"https://doi.org/10.1201/9781003190394-11","url":null,"abstract":"","PeriodicalId":10691,"journal":{"name":"Coronavirus Disease 2019 (COVID-19)","volume":"28 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78917318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global Focus and Interdisciplinary Approaches in COVID-19 Research and Their Outcomes COVID-19研究的全球焦点和跨学科方法及其成果
Coronavirus Disease 2019 (COVID-19)
Pub Date : 2022-02-07 DOI: 10.1201/9781003190394-5
H. Senol, S. Tüzmen
{"title":"Global Focus and Interdisciplinary Approaches in COVID-19 Research and Their Outcomes","authors":"H. Senol, S. Tüzmen","doi":"10.1201/9781003190394-5","DOIUrl":"https://doi.org/10.1201/9781003190394-5","url":null,"abstract":"","PeriodicalId":10691,"journal":{"name":"Coronavirus Disease 2019 (COVID-19)","volume":"65 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89324278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Evolution of COVID-19 Diagnostics COVID-19诊断方法的演变
Coronavirus Disease 2019 (COVID-19)
Pub Date : 2022-02-07 DOI: 10.1201/9781003190394-6
Praveen Rai, B. Kumar, D. V. Kumar, Prashant Kumar, Anoop Kumar, Shashi Kumar Shetty, B. Maiti
{"title":"The Evolution of COVID-19 Diagnostics","authors":"Praveen Rai, B. Kumar, D. V. Kumar, Prashant Kumar, Anoop Kumar, Shashi Kumar Shetty, B. Maiti","doi":"10.1201/9781003190394-6","DOIUrl":"https://doi.org/10.1201/9781003190394-6","url":null,"abstract":"","PeriodicalId":10691,"journal":{"name":"Coronavirus Disease 2019 (COVID-19)","volume":"320 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87660986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Therapeutic Challenges in COVID-19 COVID-19的治疗挑战
Coronavirus Disease 2019 (COVID-19)
Pub Date : 2022-02-07 DOI: 10.1201/9781003190394-3
A. Aljabali, M. Tambuwala, D. Barh, K. Lundstrom
{"title":"Therapeutic Challenges in COVID-19","authors":"A. Aljabali, M. Tambuwala, D. Barh, K. Lundstrom","doi":"10.1201/9781003190394-3","DOIUrl":"https://doi.org/10.1201/9781003190394-3","url":null,"abstract":"","PeriodicalId":10691,"journal":{"name":"Coronavirus Disease 2019 (COVID-19)","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80796743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical trials during the COVID-19 pandemic: research design and lessons COVID-19大流行期间的临床试验:研究设计和经验教训
Coronavirus Disease 2019 (COVID-19)
Pub Date : 2021-12-01 DOI: 10.1183/2312508x.10005521
H. Abo-Leyah, J. Chalmers
The COVID-19 pandemic has required a substantial coordinated international effort to develop effective treatments and vaccines, which has led to an acceleration in innovation in clinical research with the rapid adoption of pragmatic, open, adaptive platform trials for new therapeutics. Large platform trials such as RECOVERY, SOLIDARITY and REMAP-CAP have demonstrated the ability to recruit thousands of patients across multiple sites in a short period of time, resulting in therapies that have now been adopted into clinical practice. Therapies tested for COVID-19 include repurposed antivirals, immunomodulatory drugs, convalescent plasma and, more recently, novel therapeutics developed specifically to target SARS-CoV-2. Challenges have included ethical and practical issues of delivering clinical research during a pandemic, some duplication of effort and the testing of some therapies with a low likelihood of success. COVID-19 has required acceleration of the process of clinical trial conduct, from grant funding to approvals and simplification of trial processes. Many of the innovations and simplifications to clinical trial conduct that have featured so prominently during the COVID-19 pandemic are likely to be just as valuable in a post-pandemic world. An important legacy of the pandemic may be a more efficient and effective way of delivering clinical research in the future.Copyright © ERS 2021.
COVID-19大流行要求国际社会大力协调努力，开发有效的治疗方法和疫苗，这导致临床研究创新加速，新疗法迅速采用务实、开放、适应性的平台试验。RECOVERY、SOLIDARITY和REMAP-CAP等大型平台试验已经证明，它们能够在短时间内在多个地点招募数千名患者，从而产生现已被临床实践采用的治疗方法。针对COVID-19测试的疗法包括重新使用抗病毒药物、免疫调节药物、恢复期血浆，以及最近专门针对SARS-CoV-2开发的新疗法。挑战包括在大流行期间进行临床研究的伦理和实际问题、一些重复工作以及测试一些成功可能性较低的疗法。COVID-19要求加快临床试验过程，从拨款资助到批准和简化试验过程。在COVID-19大流行期间如此突出的许多临床试验行为的创新和简化，在大流行后的世界可能同样有价值。大流行的一个重要遗产可能是在未来提供更高效和有效的临床研究方式。版权所有©ERS 2021。
{"title":"Clinical trials during the COVID-19 pandemic: research design and lessons","authors":"H. Abo-Leyah, J. Chalmers","doi":"10.1183/2312508x.10005521","DOIUrl":"https://doi.org/10.1183/2312508x.10005521","url":null,"abstract":"The COVID-19 pandemic has required a substantial coordinated international effort to develop effective treatments and vaccines, which has led to an acceleration in innovation in clinical research with the rapid adoption of pragmatic, open, adaptive platform trials for new therapeutics. Large platform trials such as RECOVERY, SOLIDARITY and REMAP-CAP have demonstrated the ability to recruit thousands of patients across multiple sites in a short period of time, resulting in therapies that have now been adopted into clinical practice. Therapies tested for COVID-19 include repurposed antivirals, immunomodulatory drugs, convalescent plasma and, more recently, novel therapeutics developed specifically to target SARS-CoV-2. Challenges have included ethical and practical issues of delivering clinical research during a pandemic, some duplication of effort and the testing of some therapies with a low likelihood of success. COVID-19 has required acceleration of the process of clinical trial conduct, from grant funding to approvals and simplification of trial processes. Many of the innovations and simplifications to clinical trial conduct that have featured so prominently during the COVID-19 pandemic are likely to be just as valuable in a post-pandemic world. An important legacy of the pandemic may be a more efficient and effective way of delivering clinical research in the future.Copyright © ERS 2021.","PeriodicalId":10691,"journal":{"name":"Coronavirus Disease 2019 (COVID-19)","volume":"69 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81417035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Historical perspective: other human coronavirus infectious diseases, SARS and MERS 历史视角:其他人类冠状病毒传染病，SARS和MERS
Coronavirus Disease 2019 (COVID-19)
Pub Date : 2021-12-01 DOI: 10.1183/2312508x.10025620
D. Hui, Alimuddin Zumla
Alphacoronaviruses (HCoV-229E and HCoV-NL63) and betacoronaviruses (HCoV-OC43 and HCoV-HKU1) are common causes of upper respiratory tract infection in humans. SARS-CoV-1 and MERS-CoV emerged in 2002 and 2012, respectively, with the potential of causing severe and lethal disease in humans, termed SARS and MERS, respectively. Bats appear to be the common natural source of SARS-like coronaviruses including SARS-CoV-1, but their role in MERS-CoV is less clear. Civet cats and dromedary camels are the intermediary animal sources for SARS-CoV-1 and MERS-CoV, respectively. Nosocomial outbreaks are hallmarks of SARS and MERS. MERS patients with comorbidities or immunosuppression tend to progress more rapidly to respiratory failure and have a higher case fatality rate than SARS patients. SARS has disappeared since 2004, while there are still sporadic cases of MERS in the Middle East. Continued global surveillance is essential for SARS-like coronaviruses and MERS-CoV to monitor changing epidemiology due to viral variants.Copyright © ERS 2021.
甲型冠状病毒(HCoV-229E和HCoV-NL63)和乙型冠状病毒(HCoV-OC43和HCoV-HKU1)是人类上呼吸道感染的常见原因。SARS- cov -1和MERS- cov分别于2002年和2012年出现，具有在人类中引起严重和致命疾病的潜力，分别被称为SARS和MERS。蝙蝠似乎是sars样冠状病毒(包括SARS-CoV-1)的常见天然来源，但它们在MERS-CoV中的作用尚不清楚。果子狸和单峰骆驼分别是SARS-CoV-1和MERS-CoV的中间动物来源。医院暴发是SARS和中东呼吸综合征的标志。伴有合并症或免疫抑制的MERS患者往往会更快发展为呼吸衰竭，病死率高于SARS患者。SARS自2004年以来已经消失，而中东呼吸综合征在中东地区仍有零星病例。持续的全球监测对于监测由病毒变异引起的流行病学变化至关重要。版权所有©ERS 2021。
{"title":"Historical perspective: other human coronavirus infectious diseases, SARS and MERS","authors":"D. Hui, Alimuddin Zumla","doi":"10.1183/2312508x.10025620","DOIUrl":"https://doi.org/10.1183/2312508x.10025620","url":null,"abstract":"Alphacoronaviruses (HCoV-229E and HCoV-NL63) and betacoronaviruses (HCoV-OC43 and HCoV-HKU1) are common causes of upper respiratory tract infection in humans. SARS-CoV-1 and MERS-CoV emerged in 2002 and 2012, respectively, with the potential of causing severe and lethal disease in humans, termed SARS and MERS, respectively. Bats appear to be the common natural source of SARS-like coronaviruses including SARS-CoV-1, but their role in MERS-CoV is less clear. Civet cats and dromedary camels are the intermediary animal sources for SARS-CoV-1 and MERS-CoV, respectively. Nosocomial outbreaks are hallmarks of SARS and MERS. MERS patients with comorbidities or immunosuppression tend to progress more rapidly to respiratory failure and have a higher case fatality rate than SARS patients. SARS has disappeared since 2004, while there are still sporadic cases of MERS in the Middle East. Continued global surveillance is essential for SARS-like coronaviruses and MERS-CoV to monitor changing epidemiology due to viral variants.Copyright © ERS 2021.","PeriodicalId":10691,"journal":{"name":"Coronavirus Disease 2019 (COVID-19)","volume":"366 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83024041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Post-COVID-19 sequelae Post-COVID-19后遗症
Coronavirus Disease 2019 (COVID-19)
Pub Date : 2021-12-01 DOI: 10.1183/2312508x.10024420
A. Gramegna, M. Mantero, F. Amati, S. Aliberti, F. Blasi
This chapter explores the currently available knowledge (as at October 2021) about the long-term clinical consequences of COVID-19. Distinction between cardiorespiratory and extra-cardiorespiratory sequelae can facilitate understanding of the post-COVID sequelae problem and may aid the clinical management of patients. The strength of the recommendations is highlighted at the end of each paragraph.Copyright © ERS 2021.
本章探讨了关于COVID-19长期临床后果的现有知识(截至2021年10月)。区分心肺和心肺外后遗症有助于了解新冠肺炎后后遗症问题，有助于患者的临床管理。建议的力度在每一段的末尾突出显示。版权所有©ERS 2021。
{"title":"Post-COVID-19 sequelae","authors":"A. Gramegna, M. Mantero, F. Amati, S. Aliberti, F. Blasi","doi":"10.1183/2312508x.10024420","DOIUrl":"https://doi.org/10.1183/2312508x.10024420","url":null,"abstract":"This chapter explores the currently available knowledge (as at October 2021) about the long-term clinical consequences of COVID-19. Distinction between cardiorespiratory and extra-cardiorespiratory sequelae can facilitate understanding of the post-COVID sequelae problem and may aid the clinical management of patients. The strength of the recommendations is highlighted at the end of each paragraph.Copyright © ERS 2021.","PeriodicalId":10691,"journal":{"name":"Coronavirus Disease 2019 (COVID-19)","volume":"57 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83072693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Respiratory failure in COVID-19: a patient's perspective and clinical cases COVID-19呼吸衰竭:患者视角和临床病例
Coronavirus Disease 2019 (COVID-19)
Pub Date : 2021-12-01 DOI: 10.1183/2312508x.10025320
F. Amati, A. Vigni, Sofia Misuraca, Francesco Bindo, A. Gramegna, A. Voza, F. Blasi, S. Aliberti
The major morbidity and mortality from COVID-19 is due to acute viral pneumonitis that evolves to ARDS. Furthermore, COVID-19 patients may be affected by extrarespiratory involvement, including cardiac, renal, neurological and vascular complications. Different hospitals reorganised their logistical structures to optimise the care of COVID-19 patients and ensure infection control, and the public health scenario worldwide was characterised by the rapid spread of multidisciplinary units specifically dedicated to COVID-19 patients. This chapter describes the personal experience and clinical case of a previously healthy and active patient who suffered from severe COVID-19. Two other cases of patients hospitalised because of severe acute respiratory failure due to COVID-19 are also discussed.Copyright © ERS 2021.
COVID-19的主要发病率和死亡率是由于发展为ARDS的急性病毒性肺炎。此外，COVID-19患者可能受到呼吸外受累的影响，包括心脏、肾脏、神经和血管并发症。不同的医院重组了他们的后勤结构，以优化对COVID-19患者的护理并确保感染控制，全球公共卫生形势的特点是专门针对COVID-19患者的多学科单位迅速蔓延。本章描述了一位健康活动的重症患者的个人经历和临床病例。本文还讨论了另外两例因COVID-19引起的严重急性呼吸衰竭而住院的患者。版权所有©ERS 2021。
{"title":"Respiratory failure in COVID-19: a patient's perspective and clinical cases","authors":"F. Amati, A. Vigni, Sofia Misuraca, Francesco Bindo, A. Gramegna, A. Voza, F. Blasi, S. Aliberti","doi":"10.1183/2312508x.10025320","DOIUrl":"https://doi.org/10.1183/2312508x.10025320","url":null,"abstract":"The major morbidity and mortality from COVID-19 is due to acute viral pneumonitis that evolves to ARDS. Furthermore, COVID-19 patients may be affected by extrarespiratory involvement, including cardiac, renal, neurological and vascular complications. Different hospitals reorganised their logistical structures to optimise the care of COVID-19 patients and ensure infection control, and the public health scenario worldwide was characterised by the rapid spread of multidisciplinary units specifically dedicated to COVID-19 patients. This chapter describes the personal experience and clinical case of a previously healthy and active patient who suffered from severe COVID-19. Two other cases of patients hospitalised because of severe acute respiratory failure due to COVID-19 are also discussed.Copyright © ERS 2021.","PeriodicalId":10691,"journal":{"name":"Coronavirus Disease 2019 (COVID-19)","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75257817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Coronavirus Disease 2019 (COVID-19)
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1